Plozasiran Therapy in Patients With Severe Hypertriglyceridaemia: Twelve-Month Clinical Results

“We continue to see plozasiran data as best in class with respect to safety, activity, efficacy, and convenience, with dosing only four times per year, and we are more confident than ever in its promise. These compelling Phase 3 data in a broad sHTG study population that closely resembles today's diverse patient landscape demonstrate plozasiran's potential to dramatically change the way people are treated.”

“These strong results from the Phase 3 SHASTA-3 and SHASTA-4 studies, evaluating plozasiran in patients with sHTG, build upon the promising results from prior Phase 2 and Phase 3 studies across various patient populations, including those with moderate hypertriglyceridemia, mixed hyperlipidemia, severe hypertriglyceridemia, and genetically confirmed and clinically diagnosed familial chylomicronemia syndrome. Plozasiran continues to demonstrate deep and durable pharmacodynamic effects with a consistently favorable safety and tolerability profile, including a highly encouraging liver safety profile.”

“These findings highlight the potential of plozasiran as a promising therapy for patients across the spectrum of sHTG.”